Ramot, the tech transfer office (TTO) of Tel Aviv University, has signed a research collaboration agreement with Aerie Pharmaceuticals to develop treatments for glaucoma and other eye diseases.
The two will be working together from the discovery stage all the way through to commercialisation. Aerie will be responsible for R&D activities, and will pay Ramot development milestone payments as well as royalty payments on any successful commercialisation which comes from the partnership.
The main focus of the partnership will be a preclinical small molecule product for dry age-related macular degeneration.
Shlomo Nimrodi, Ramot’s CEO, said: “We believe Aerie is the right partner to explore the full potential of this exciting molecule in ophthalmology. We have observed solid preclinical evidence that beta amyloid is a compelling target for both glaucoma and dry AMD, and we have great confidence that Aerie will pursue this opportunity with a high level of scientific acumen and diligence.”
